Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 1.00 |
| ▸ | UGCG | Q16739 | 2/20 | 0.61 |
| ▸ | CERT1 | Q9Y5P4 | 3/20 | 0.61 |
| ▸ | SMPD2 | O60906 | 2/20 | 0.59 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4234738 | 1.00 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL13930310 | 1.00 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL8341673 | 1.00 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL4239949 | 1.00 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL13930311 | 1.00 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL8340882 | 1.00 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL13930314 | 1.00 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL360960 | 1.00 | ASAH1 (1.00) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL27657658 | 0.94 | ASAH1 (0.89) | ASAH1ALDH1A1ACER2UGCGCERT1 | |
| SCHEMBL12435699 | 0.92 | ASAH1 (0.85) | ASAH1ALDH1A1ACER2UGCGCERT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. | 2022-06-16 | — | — | US | claimed |
| WO-2020023390-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. (US) | 2020-01-30 | — | — | WO | claimed |
| US-20250367471-A1 | PERFUSION MODULATED TUMOR DOSE SCULPTING WITH SINGLE DOSE RADIOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-12-04 | — | — | US | disclosed |
| US-12214218-B2 | Perfusion modulated tumor dose sculpting with single dose radiotherapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-02-04 | — | — | US | disclosed |
| WO-2024211811-A2 | METHODS AND COMPOSITIONS FOR ANTIBODY-DRUG CONJUGATES | FREZENT BIOLOGICAL SOLUTIONS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-07-13 | — | — | US | disclosed |
| WO-2022261752-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PARKER ALEX (CA) | 2022-12-22 | — | — | WO | disclosed |
| US-20220387358-A1 | CERAMIDE ANALOG SACLAC MODULATES SPHINGOLIPID LEVELS AND MCL-1 SPLICING TO INDUCE APOPTOSIS IN ACUTE MYELOID LEUKEMIA | UNIV VIRGINIA PATENT FOUNDATION (US) | 2022-12-08 | — | — | US | disclosed |
| US-11479802-B2 | Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family | REGENERON PHARMACEUTICALS, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-20220296926-A1 | PERFUSION MODULATED TUMOR DOSE SCULPTING WITH SINGLE DOSE RADIOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-09-22 | — | — | US | disclosed |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20050182020-A1 | Ceramide de novo synthesis-based therapeutic and prophylactic methods, and related articles of manufacture | WORGALL TILLA S (US) | 2005-08-18 | — | — | US | disclosed |
| US-6881546-B2 | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor | MEDLYTE, INC., SDSU HEART INSTITUTE (US) | 2005-04-19 | — | — | US | disclosed |
| US-6858383-B2 | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor | MEDLYTE, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040247603-A1 | Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation | MEDLYTE, INC. | 2004-12-09 | — | — | US | disclosed |
| US-20030096022-A1 | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor | MEDLYTE, INC. | 2003-05-22 | — | — | US | disclosed |
| US-20030064936-A1 | Use of sphingoid base for inhibiting ceramidase activity | COSMOFERM B.V. (NL) | 2003-04-03 | — | — | US | disclosed |
| EP-1287815-A1 | Use of a sphingoid base for inhibiting ceramidase activity | Cosmoferm B.V. (NL) | 2003-03-05 | — | — | EP | disclosed |
| US-20030026799-A1 | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor | MEDLYTE, INC. | 2003-02-06 | — | — | US | disclosed |
| US-20030027304-A1 | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor | MEDLYTE, INC. | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040247603-A1 | Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation | SGMS2, SGMS1, CD47 | ASAH1 48/4885ALDH1A1 1758/4885ACER2 101/4885 |
| US-20220296926-A1 | PERFUSION MODULATED TUMOR DOSE SCULPTING WITH SINGLE DOSE RADIOTHERAPY | TP53, CTPS1, TSG101 | ASAH1 770/4885ALDH1A1 2903/4885ACER2 629/4885 |
| US-20030026799-A1 | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor | SPHK1, SGPL1, SGMS1 | ASAH1 18/4885ALDH1A1 706/4885ACER2 49/4885 |
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | HSP90AB1, HSP90AA1, HSF1 | ASAH1 3335/4885ALDH1A1 3755/4885ACER2 4503/4885 |
| US-12214218-B2 | Perfusion modulated tumor dose sculpting with single dose radiotherapy | TP53, CTPS1, TSG101 | ASAH1 770/4885ALDH1A1 2903/4885ACER2 629/4885 |
| US-20030064936-A1 | Use of sphingoid base for inhibiting ceramidase activity | ASAH2, ASAH1, ACER2 | ASAH1 2/4885ALDH1A1 2712/4885ACER2 3/4885 |
| US-20030027304-A1 | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor | SPHK1, SGPL1, SGMS1 | ASAH1 18/4885ALDH1A1 706/4885ACER2 49/4885 |
| US-20250367471-A1 | PERFUSION MODULATED TUMOR DOSE SCULPTING WITH SINGLE DOSE RADIOTHERAPY | TP53, CTPS1, TSG101 | ASAH1 770/4885ALDH1A1 2903/4885ACER2 629/4885 |
| US-20030096022-A1 | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor | SPHK1, SGPL1, SGMS1 | ASAH1 18/4885ALDH1A1 706/4885ACER2 49/4885 |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | GAA, GBA1, GBA2 | ASAH1 8/4885ALDH1A1 2142/4885ACER2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.